Zobrazeno 1 - 10
of 988
pro vyhledávání: '"drug delivery to the brain"'
Autor:
Sukanya Bhunia, Nagesh Kolishetti, Arti Vashist, Adriana Yndart Arias, Deborah Brooks, Madhavan Nair
Publikováno v:
Pharmaceutics, Vol 15, Iss 12, p 2658 (2023)
Brain cancers and neurodegenerative diseases are on the rise, treatments for central nervous system (CNS) diseases remain limited. Despite the significant advancement in drug development technology with emerging biopharmaceuticals like gene therapy o
Externí odkaz:
https://doaj.org/article/ad9790e7e99649ecb25f785c13d8fbc2
Autor:
Toshihiko Tashima
Publikováno v:
Antibodies, Vol 12, Iss 3, p 43 (2023)
Drug development for neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease has challenging difficulties due to the pharmacokinetic impermeability based on the blood-brain barrier (BBB) as well as
Externí odkaz:
https://doaj.org/article/53f756a743ab47d1a44cc78f91a96a7e
Autor:
Yamir Islam, Andrew G. Leach, Jayden Smith, Stefano Pluchino, Christopher R. Coxon, Muttuswamy Sivakumaran, James Downing, Amos A. Fatokun, Meritxell Teixidò, Touraj Ehtezazi
Publikováno v:
Advanced Science, Vol 8, Iss 11, Pp n/a-n/a (2021)
Abstract The prevalence of neurological/neurodegenerative diseases, such as Alzheimer's disease is known to be increasing due to an aging population and is anticipated to further grow in the decades ahead. The treatment of brain diseases is challengi
Externí odkaz:
https://doaj.org/article/3eafd854a90a43b892f923af6f962f04
Publikováno v:
Nanoscale Research Letters, Vol 14, Iss 1, Pp 1-14 (2019)
Abstract This bibliometric study investigated the public trends in the fields of nanoparticles which is limited to drug delivery and magnetic nanoparticles’ literature published from 1980 to October 2017. The data were collected from the Web of Sci
Externí odkaz:
https://doaj.org/article/9ee7085b12a0437f81ee173fef618b2a
Autor:
Toshihiko Tashima
Publikováno v:
Biomedicines, Vol 10, Iss 7, p 1597 (2022)
Advances in pharmacotherapy have brought extraordinary benefits to humanity. However, unmet medical needs in patients remain, particularly in the treatment of central nervous system (CNS) diseases and cancers. CNS drug delivery into the brain across
Externí odkaz:
https://doaj.org/article/1f80ef6c278f4a0f8ef118cf617e5216
Autor:
Toshihiko Tashima
Publikováno v:
Pharmaceutics, Vol 14, Iss 2, p 411 (2022)
Alzheimer’s disease (AD) is a neurodegenerative disease that causes memory loss, cognitive decline, and eventually dementia. The etiology of AD and its pathological mechanisms remain unclear due to its complex pathobiology. At the same time, the nu
Externí odkaz:
https://doaj.org/article/03c4a2ed3d2c47259efbbd4037e569f4
Publikováno v:
Current Pharmaceutical Design. 27:4388-4403
Drug delivery to the brain has been a significant challenge in treating neurodegenerative disorders such as Alzheimer's disease due to the presence of the blood-brain barrier, which primarily obstructs the access of drugs and biomolecules into the br
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e95ebc9bae2bee150abcb411cf5ba534
https://doi.org/10.2174/1381612827666210927163258
https://doi.org/10.2174/1381612827666210927163258
Autor:
Reiner F. Haseloff, Giovanna del Vecchio, Christian Tscheik, Sophie Dithmer, Wolfgang Walther, Olga Breitkreuz-Korff, Leif Schröder, Lars Winkler, Hartwig Wolburg, Ingolf E. Blasig, Andrea Orthmann
Publikováno v:
Journal of Controlled Release. 338:137-148
Drug delivery to the brain is limited for most pharmaceuticals by the blood-brain barrier (BBB) where claudin-5 dominates the paraendothelial tightening. For circumventing the BBB, we identified the compound M01 as a claudin-5 interaction inhibitor.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91a0492a6621bacfa6a68ff1d236ee4a
https://doi.org/10.1016/j.jconrel.2021.08.014
https://doi.org/10.1016/j.jconrel.2021.08.014
Autor:
Hongchae Baek, Dezhuang Ye, Yaoheng Yang, Jinyun Yuan, Hong Chen, Arash Nazeri, Si Chen, Joshua B. Rubin
Publikováno v:
J Cereb Blood Flow Metab
Focused ultrasound combined with circulating microbubbles (FUS+MB) can transiently enhance blood-brain barrier (BBB) permeability at targeted brain locations. Its great promise in improving drug delivery to the brain is reflected by a rapidly growing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bcd16fe7a31a61bbf968a53595941af
https://doi.org/10.1177/0271678x211046129
https://doi.org/10.1177/0271678x211046129
Autor:
Yosuke Hashimoto, Keisuke Tachibana, Hiroyuki Takeda, Keisuke Shirakura, Masuo Kondoh, Yoshiaki Okada, Hiroki Kuniyasu, Yumi Iwashita, Yukio Ago, Itsuki Nishino, Ryuichi Hirayama
Publikováno v:
Journal of Controlled Release. 336:105-111
Claudin-5 (CLDN-5) is an essential component of the tight junction seal in the blood–brain barrier. Previously, we showed that CLDN-5 modulation in vitro via an anti-CLDN-5 monoclonal antibody (mAb) may be useful for increasing the permeability of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c29707d12bd80e4ddaf570d914394779
https://doi.org/10.1016/j.jconrel.2021.06.009
https://doi.org/10.1016/j.jconrel.2021.06.009